NovaBridge Biosciences (NASDAQ:NBP) Sees Shift in Consensus Price Target
I-Mab(US:IMAB) Financial Modeling Prepยท2025-11-17 02:00The average price target for NovaBridge Biosciences (NASDAQ:NBP) has decreased from $7.75 to $7.00 in the past month, indicating a slight decline in analyst optimism.NovaBridge's strategic partnerships and promising immuno-oncology agents in clinical trials highlight its potential in cancer treatment.Contrastingly, IMab (NASDAQ:IMAB) receives an upgrade to a Zacks Rank #2 (Buy), with a price target of $8, suggesting differing analyst views on these biotech companies.NovaBridge Biosciences (NASDAQ:NBP) is a ...